Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 101

Sort by

Sort Order Select

Journal Articles

A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL-RR1/CELESTIAL-RRCLL)

Blood (2025) 146 (Supplement 1): 2137.

https://doi.org/10.1182/blood-2025-2137

Published: 2025

Journal Articles

Pola-R-CHP in previously untreated low-risk (IPI 0-1) DLBCL: A nationwide multicenter retrospective study in China

Blood (2025) 146 (Supplement 1): 7229.

https://doi.org/10.1182/blood-2025-7229

Published: 2025

Journal Articles

Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma

Yuhong Ren, Yang Ke, Zhixiang Cheng, Ling Yuan, Weiguang Wang, Jingli Zhuang, Luya Cheng, Yue Wang, Jiadai Xu, Xuejiao Zhang, Jing Li, Peng Liu

Blood (2025) 146 (Supplement 1): 7257.

https://doi.org/10.1182/blood-2025-7257

Published: 2025

Journal Articles

Longitudinal single-cell profiling in canine DLBCL reveals regulatory networks driving chemotherapy resistance.

Steven Tur, Yinghua Wang, Peng Liu, Ashley Zuzick, Ann Marie Picone, Susannah Sample, Lixin Rui, Marjorie Brand, Xuan Pan

Blood (2025) 146 (Supplement 1): 1788.

https://doi.org/10.1182/blood-2025-1788

Published: 2025

Journal Articles

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Blood (2025) 146 (Supplement 1): 475.

https://doi.org/10.1182/blood-2025-475

Published: 2025

Journal Articles

An exploratory study to evaluate the safety and efficacy of autologous CAR-T cells with dual targeting of BCMA and CD19 (FKC289 Injection) in subjects with relapsed or refractory systemic light chain amyloidosis

Jing Li, Shiyang Gu, Yuhong Ren, Yang Yang, Jiadai Xu, Yian Zhang, Tianhong Xu, Xiaochen Wang, Xiaojiao Zhao, He Xin, Zisong Zhou, Peng Liu

Blood (2025) 146 (Supplement 1): 7674.

https://doi.org/10.1182/blood-2025-7674

Published: 2025

Journal Articles

Pre-diagnostic biomarkers show disease susceptibility continuum and enable early prediction of multiple myeloma

Jiadai Xu, Bingjie Li, Zhigang Yao, Peng Liu

Blood (2025) 146 (Supplement 1): 2231.

https://doi.org/10.1182/blood-2025-2231

Published: 2025

Journal Articles

Pola-R-CHP in newly diagnosed primary mediastinal B-cell lymphoma:high efficacy and tolerability

Xue Yang, Yuhong Ren, Luya Cheng, Peng Liu

Blood (2025) 146 (Supplement 1): 3682.

https://doi.org/10.1182/blood-2025-3682

Published: 2025

Journal Articles

Phase 2 Study of polatuzumab vedotin, zanubrutinib and rituximab (Pola-ZR) in untreated elderly and frail DLBCL patients: Molecular features and follow-up updates

Yuhong Ren, Jing Li, Zhixiang Cheng, Jingli Zhuang, Hui Tan, Luya Cheng, Ling Yuan, Yang Ke, Peng Liu

Blood (2025) 146 (Supplement 1): 1917.

https://doi.org/10.1182/blood-2025-1917

Published: 2025

Journal Articles

Preliminary results from a phase 1/1b first-in-human study of BGB-21447, a next-generation BCL2 inhibitor, in patients with B-cell non-Hodgkin lymphoma

Fei Li, Stephen Opat, Dengju Li, Keshu Zhou, Peng Liu, Wei Yang, Chan Cheah, Tingyu Wang, Yu Yang, Caixia Li, Hongmei Jing, Henry Ngu, Lipeng Chen, Ting Deng, Fangjie Xie, Naisargee Shah, Zhao Xu, Richard Delarue, Jianyong Li

Blood (2025) 146 (Supplement 1): 1910.

https://doi.org/10.1182/blood-2025-1910

Published: 2025

Journal Articles

Efficacy and safety of pola-ICE, with or without rituximab in relapsed/refractory diffuse large B-cell lymphoma: A real-world multicenter study

Huiqiang Huang, Xuan-Ye Zhang, Jicheng Hong, Gao Yan, Peng Liu, Kai Hu, Jingping Pi, Rui Liu, Haoqing Chen, Jialing Zhuang

Blood (2025) 146 (Supplement 1): 7208.

https://doi.org/10.1182/blood-2025-7208

Published: 2025

Journal Articles

Updated results of TQB2934, a novel 2+1 BCMA × CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: A phase I study

Yian Zhang, Bingzong Li, Junling Zhuang, Pengcheng He, Xingli Zhao, Baijun Fang, Songfu Jiang, Bing Chen, Zhongjun Xia, Zhenyu Li, Zengjun Li, Haifeng Zhao, Dawei Ding, Qianqian Zhang, Xunqiang Wang, Peng Liu

Blood (2025) 146 (Supplement 1): 2279.

https://doi.org/10.1182/blood-2025-2279

Published: 2025

Journal Articles

Initial Results of the first-in-human Phase 1 study of IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA and CD3, in patients with relapsed or refractory multiple myeloma

Jing Li, Zhenyu Li, Chunrui Li, Pengcheng He, Jun Luo, Rong Fu, Liye Zhong, Hang Quach, Jay Hocking, Peter Presgrave, Xiaoyi Tang, Wen Zhang, Jinchao Gao, Luyin Ding, Peiqi Li, Hui Zhou, Peng Liu

Blood (2025) 146 (Supplement 1): 702.

https://doi.org/10.1182/blood-2025-702

Published: 2025

Journal Articles

Organ dysfunction in pediatric patients with HSCT-TMA treated with ravulizumab

Sonali Chaudhury, David Bueno, Jude Fry, Eric Bachman, Peng Liu, Elsa Konig, Cory Williams, Aviva Krauss, Sarah Lawson, Michelle Schoettler, Yoshiyuki Takahashi, Christopher Dvorak, Franco Locatelli

Blood (2025) 146 (Supplement 1): 4266.

https://doi.org/10.1182/blood-2025-4266

Published: 2025

Journal Articles

High-throughput single-cell lipidomics reveals stage-specific phospholipid remodeling and ferroptosis-related signatures in the Evolution of plasma cell dyscrasia

Fujing Zhang, Chenxi Cao, Junling Zhuang, Peng Liu, Xiaoxiao Ma

Blood (2025) 146 (Supplement 1): 7458.

https://doi.org/10.1182/blood-2025-7458

Published: 2025

Journal Articles

Real-world use of Pola-R-CHP for untreated diffuse large B-cell lymphoma (DLBCL): A systematic literature review

Peng Liu, Koji Kato, Sai Li, Lara Chayab, Adriano Sa, Connie Lee Batlevi, Matthew Matasar

Blood (2025) 146 (Supplement 1): 8082.

https://doi.org/10.1182/blood-2025-8082

Published: 2025

Journal Articles

Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH

Austin Kulasekararaj, Morag Griffin, Caroline Piatek, Jamile Shammo, Jun-ichi Nishimura, Christopher Patriquin, Hubert Schrezenmeier, Wilma Barcellini, Jens Panse, Anna Gaya, Yogesh Patel, Peng Liu, Gleb Filippov, Flore Sicre de Fontbrune, Antonio Risitano, Jong Wook Lee

Blood (2025) 145 (8): 811–822.

https://doi.org/10.1182/blood.2024026299

Published: 2025

Includes: Supplemental data

Journal Articles

GATA2 Genetic Variant-Induced Pathogenesis: Loss-of-Function and Gain-of-Function Mechanisms

Koichi R. Katsumura, Peng Liu, Jeong-Ah Kim, Charu Mehta, Vu L. Tran, Mabel M. Jung, Kirby D. Johnson, Emery H. Bresnick

Blood (2024) 144 (Supplement 1): 4091.

https://doi.org/10.1182/blood-2024-208365

Published: 2024

Journal Articles

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Blood (2024) 144 (Supplement 1): 4748.

https://doi.org/10.1182/blood-2024-202893

Published: 2024

Journal Articles

Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study

Chunrui Li, Dehui Zou, Di Wang, Baijun Fang, He Huang, Jianyong Li, Bing Chen, Jing Liu, Xi Zhang, Yujun Dong, Kai Hu, Peng Liu, Jianqing Mi, Kaiyang Ding, Zhenyu Li, Qie Dong, Fuyuan Zhang, Guang Hu, Lu-Gui Qiu

Blood (2024) 144 (Supplement 1): 4761.

https://doi.org/10.1182/blood-2024-204355

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL-RR1/CELESTIAL-RRCLL)

Pola-R-CHP in previously untreated low-risk (IPI 0-1) DLBCL: A nationwide multicenter retrospective study in China

Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma

Longitudinal single-cell profiling in canine DLBCL reveals regulatory networks driving chemotherapy resistance.

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

An exploratory study to evaluate the safety and efficacy of autologous CAR-T cells with dual targeting of BCMA and CD19 (FKC289 Injection) in subjects with relapsed or refractory systemic light chain amyloidosis

Pre-diagnostic biomarkers show disease susceptibility continuum and enable early prediction of multiple myeloma

Pola-R-CHP in newly diagnosed primary mediastinal B-cell lymphoma:high efficacy and tolerability

Phase 2 Study of polatuzumab vedotin, zanubrutinib and rituximab (Pola-ZR) in untreated elderly and frail DLBCL patients: Molecular features and follow-up updates

Preliminary results from a phase 1/1b first-in-human study of BGB-21447, a next-generation BCL2 inhibitor, in patients with B-cell non-Hodgkin lymphoma

Efficacy and safety of pola-ICE, with or without rituximab in relapsed/refractory diffuse large B-cell lymphoma: A real-world multicenter study

Updated results of TQB2934, a novel 2+1 BCMA × CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: A phase I study

Initial Results of the first-in-human Phase 1 study of IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA and CD3, in patients with relapsed or refractory multiple myeloma

Organ dysfunction in pediatric patients with HSCT-TMA treated with ravulizumab

High-throughput single-cell lipidomics reveals stage-specific phospholipid remodeling and ferroptosis-related signatures in the Evolution of plasma cell dyscrasia

Real-world use of Pola-R-CHP for untreated diffuse large B-cell lymphoma (DLBCL): A systematic literature review

Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH

GATA2 Genetic Variant-Induced Pathogenesis: Loss-of-Function and Gain-of-Function Mechanisms

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only